102449-34-3

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 4-(diphenylmethylene)-, ethyl ester
• CAS NO: 102449-34-3
• Molecular Formula: C21H23NO2
• Molecular Weight: 321.419
• Mol File: 102449-34-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 4-(diphenylmethylene)-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 4-(diphenylmethylene)-, ethyl ester(102449-34-3)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 4-(diphenylmethylene)-, ethyl ester(102449-34-3)

Safety Data

• Hazardous Substances Data: 102449-34-3(Hazardous Substances Data)

Upstream product

• 6071-93-8 NSC 31633 
• 541-41-3 chloroformic acid ethyl ester 
• 119-61-9 benzophenone 
• 29976-53-2 N-ethoxycarbonyl-4-piperidone 

Downstream Products

• 50706-57-5 4-(diphenylmethylene)piperidine 
• 100169-94-6 1,1-dimethyl-4-(diphenylmethylene)piperidinium iodide 
• 688304-93-0 6-(4-Benzhydrylidene-piperidin-1-yl)-hexanoic acid methyl ester 
• 137406-19-0 5-(4-Benzhydrylidene-piperidin-1-yl)-pentanoic acid ethyl ester 
• 137406-18-9 4-(4-Benzhydrylidene-piperidin-1-yl)-butyric acid ethyl ester 
• 137406-16-7 3-(4-Benzhydrylidene-piperidin-1-yl)-propionic acid ethyl ester 
• 167108-56-7 (4-Benzhydrylidene-piperidin-1-yl)-acetic acid ethyl ester 
• 6071-93-8 NSC 31633 

Relevant articles and documents

Synthesis, affinity at 5-HT(2A), 5-HT(2B) and 5-HT(2C) serotonin receptors and structure-activity relationships of a series of cyproheptadine analogues

Cyproheptadine is a drug that shows high affinity for type 2 (5-HT2) receptors. We studied a series of compounds obtained by modification of the tricyclic system of Cyp (dibenzocycloheptadiene): 2f (thioxanthene), 2g (xanthene), 2h (dihydrodibenzocycloheptadiene), 2j (diphenyl), 2i (fluorene), and 3b (phenylmethyl). Their activities at the rat cerebral cortex 5-HT(2A) receptor were (pK(i) ± S.E.M.): 8.80 ± 0.11 (Cyp), 8.60 ± 0.07 (2f), 8.40 ± 0.02 (2g), 8.05 ± 0.03 (2h), 7.87 ± 0.12 (2j), 6.70±0.02 (2i) and 6.45±0.02 (3b); those at the rat stomach fundus 5-HT(2B) receptor (pA2±S.E.M.) were: 9.14±0.25 (Cyp), 8.49±0.07 (2F), 7.58±0.58 (2g), 7.02±0.14 (2h), 6.07±0.20 (2j), and undetectable (21, 3b); and those at the pig choroidal plexus 5-HT(2C) receptor (pK(i)±S.E.M.) were: 8.71 ± 0.08 (Cyp), 8.68 ± 0.01 (20, 8.58 ± 0.20 (2g), 7.95 ± 0.05 (2h), 7.57 ± 0.04 (2j), 6.98 ± 0.04 (2i) and 6.63 ± 0.20 (3b). The slopes did not differ significantly from unity. The compounds exhibited the same order of activities at every type of receptor, and the most active molecules presented certain steric (butterfly conformation of the tricyclic system) and electrostatic (proton affinity on the top of the central rings) patterns. It is concluded that the activity of cyproheptadine derivatives at 5-HT2 receptors is related to these molecular features, which make feasible a common disposition to interact with all three 5-HT2 subtypes.

TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS

The invention is directed to compositions used for treating Central Nervous System (CNS) disorders. In addition, the invention provides convenient methods of treatment of a CNS disorder. Furthermore, the invention provides methods of treating sleep disorders using compositions that remain active for a discrete period of time to reduce side effects. More specifically, the invention is directed to the compositions and use of derivatized, e.g., ester or carboxylic acid derivatized, antihistamine antagonists for the treatment of sleep disorders.

Cyproheptadine analogues: Synthesis, antiserotoninergic activity, and structure-activity relationships

A series of cyproheptadine related compounds was synthesized and tested pharmacologically. In comparison with cyproheptadine, these compounds do not have a central ring and some contain groups other than N-methyl. Synthesis was carried out with low-valent